Glenmark Launches Triple-Drug Combo For Type 2 Diabetes

Glenmark Pharma President & Business Head (India Formulations) Alok Malik said the drug helps improve the glycemic control among adult patients with high HbA1c and other co-morbidities; while also reducing major renal and cardiac adverse events
Adequate Health Coverage To Fight Diabetes
Adequate Health Coverage To Fight Diabetes

Glenmark Pharmaceuticals on Wednesday said it has launched a triple-fixed-dose combination (FDC) drug for treatment of diabetes.

The Mumbai-based drug firm has introduced the combination of Teneligliptin, Dapagliflozin and Metformin under the brand name Zita.

It is indicated to improve glycemic control in patients with Type 2 diabetes.

Priced at Rs 14 per tablet (per day), the medication lowers the daily cost of therapy by 30 per cent; making it affordable for the patients, the drug firm stated.

Glenmark Pharma President & Business Head (India Formulations) Alok Malik said the drug helps improve the glycemic control among adult patients with high HbA1c and other co-morbidities; while also reducing major renal and cardiac adverse events.

According to IQVIA sales data for the 12-month period ending August 2023, the market for oral anti-diabetic drugs in India is estimated at Rs 12,522 crore, with an annual growth of 6.5 per cent against the corresponding period last year.

Related Stories

No stories found.
logo
Outlook Business & Money
business.outlookindia.com